183 related articles for article (PubMed ID: 10681363)
1. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
[TBL] [Abstract][Full Text] [Related]
4. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
[TBL] [Abstract][Full Text] [Related]
5. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
6. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
Joly V; Moroni M; Concia E; Lazzarin A; Hirschel B; Jost J; Chiodo F; Bentwich Z; Love WC; Hawkins DA; Wilkins EG; Gatell AJ; Vetter N; Greenwald C; Freimuth WW; de Cian W
Antimicrob Agents Chemother; 2000 Nov; 44(11):3155-7. PubMed ID: 11036040
[TBL] [Abstract][Full Text] [Related]
7. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
[TBL] [Abstract][Full Text] [Related]
8. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Deeks SG
J Acquir Immune Defic Syndr; 2001 Mar; 26 Suppl 1():S25-33. PubMed ID: 11264999
[TBL] [Abstract][Full Text] [Related]
9. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
Miller V; de Béthune MP; Kober A; Stürmer M; Hertogs K; Pauwels R; Stoffels P; Staszewski S
Antimicrob Agents Chemother; 1998 Dec; 42(12):3123-9. PubMed ID: 9835502
[TBL] [Abstract][Full Text] [Related]
10. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
[TBL] [Abstract][Full Text] [Related]
12. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
14. Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
Genin MJ; Biles C; Keiser BJ; Poppe SM; Swaney SM; Tarpley WG; Yagi Y; Romero DL
J Med Chem; 2000 Mar; 43(5):1034-40. PubMed ID: 10715167
[TBL] [Abstract][Full Text] [Related]
15. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
16. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Ambrose Z; Herman BD; Sheen CW; Zelina S; Moore KL; Tachedjian G; Nissley DV; Sluis-Cremer N
J Virol; 2009 Apr; 83(8):3826-33. PubMed ID: 19193782
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
18. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
Cao YL; Li SX; Chen H; Guo Y
Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz: resistance and cross-resistance.
Clotet B
Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
[TBL] [Abstract][Full Text] [Related]
20. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
